Details of Drug-Metabolizing Enzyme (DME)

General Information of Drug-Metabolizing Enzyme (DME) (ID: DEF2WXN)

• DME Name: UDP-glucuronosyltransferase 1A3 (UGT1A3)
• Synonyms: UDP-glucuronosyltransferase family 1 member A3; UDP-glucuronosyltransferase 1-C; UDP-glucuronosyltransferase 1-3; UDPGT 1-3; UGT-1C; UGT1*3; UGT1-03; UGT1.3; UGT1A3; UGT1C
• Gene Name: UGT1A3
• UniProt ID: UD13_HUMAN
• INTEDE ID: DME0041
• Gene ID: 54659
• EC Number:
  EC: 2.4.1.17
  Transferase
  Glycosyltransferases
  Hexosyltransferase
  EC: 2.4.1.17
• Lineage:
  Species: Homo sapiens
  Kingdom: Metazoa
  Phylum: Chordata
  Class: Mammalia
  Order: Primates
  Family: Hominidae
  Genus: Homo
  Species: Homo sapiens
• Sequence:
  MATGLQVPLPWLATGLLLLLSVQPWAESGKVLVVPIDGSHWLSMREVLRELHARGHQAVV
  LTPEVNMHIKEENFFTLTTYAISWTQDEFDRHVLGHTQLYFETEHFLKKFFRSMAMLNNM
  SLVYHRSCVELLHNEALIRHLNATSFDVVLTDPVNLCAAVLAKYLSIPTVFFLRNIPCDL
  DFKGTQCPNPSSYIPRLLTTNSDHMTFMQRVKNMLYPLALSYICHAFSAPYASLASELFQ
  REVSVVDILSHASVWLFRGDFVMDYPRPIMPNMVFIGGINCANRKPLSQEFEAYINASGE
  HGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQND
  LLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMT
  SEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAH
  DLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH
• Function: This enzyme is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds.
• KEGG Pathway:
  Ascorbate and aldarate metabolism (hsa00053)
  Chemical carcinogenesis (hsa05204)
  Drug metabolism - cytochrome P450 (hsa00982)
  Drug metabolism - other enzymes (hsa00983)
  Metabolic pathways (hsa01100)
  Metabolism of xenobiotics by cytochrome P450 (hsa00980)
  Pentose and glucuronate interconversions (hsa00040)
  Porphyrin and chlorophyll metabolism (hsa00860)
  Retinol metabolism (hsa00830)
  Steroid hormone biosynthesis (hsa00140)
• Reactome Pathway:
  NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis (R-HSA-9623433)
  Glucuronidation (R-HSA-156588)

Molecular Interaction Atlas (MIA) of This DME

34 Approved Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ambrisentan	DMD1QXW	Pulmonary arterial hypertension	BB01.0	Approved	[1]
Anastrozole	DMNP60F	Breast cancer	2C60-2C65	Approved	[2]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[3]
Baloxavir marboxil	DM1UV7F	Influenza virus infection	1E30-1E32	Approved	[4]
Candesartan	DMRK8OT	Chronic heart failure	BD1Z	Approved	[5]
Cerivastatin	DMXCM7H	Hyperlipidaemia	5C80	Approved	[6]
Cyproheptadine	DM92AH3	Allergic rhinitis	CA08.0	Approved	[7]
Darolutamide	DMV7YFT	Prostate cancer	2C82.0	Approved	[8]
Deferasirox	DM6ETS0	Beta thalassemia	3A50.2	Approved	[9]
Dexibuprofen	DMFYBD0	Ankylosing spondylitis	FA92.0	Approved	[5]
Diclofenac	DMPIHLS	Chronic renal failure	GB61.Z	Approved	[10]
Empagliflozin	DMRF9YK	Type-1 diabetes	5A10	Approved	[11]
Etodolac	DM6WJO9	Osteoarthritis	FA00-FA05	Approved	[5]
Ezetimibe	DM7A8TW	Atherosclerosis	BD40	Approved	[12]
Flurbiprofen	DMGN4BY	Osteoarthritis	FA00-FA05	Approved	[5]
Gemfibrozil	DMD8Q3J	Hyperlipidaemia	5C80	Approved	[13]
Hydromorphone	DMHP21E	Back pain	ME84.Z	Approved	[14]
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[5]
Irbesartan	DMTP1DC	Diabetic kidney disease	GB61.Z	Approved	[5]
Ketotifen	DM74XKS	Allergic conjunctivitis	9A60.02	Approved	[]
Lamotrigine	DM8SXYG	Bipolar disorder	6A60	Approved	[15]
Lorlatinib	DMICDLV	Non-small-cell lung cancer	2C25.Y	Approved	[16]
Losartan	DM72JXH	Diabetic kidney disease	GB61.Z	Approved	[5]
Lovastatin	DM9OZWQ	Arteriosclerosis	BD40	Approved	[17]
Mitiglinide	DMP8HEL	Diabetic complication	5A2Y	Approved	[5]
Morphine	DMRMS0L	Advanced cancer	2A00-2F9Z	Approved	[7]
Naproxen	DMZ5RGV	Bursitis		Approved	[18]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[19]
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[20]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[17]
Telmisartan	DMS3GX2	Hypertension	BA00-BA04	Approved	[21]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[22]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[23]
Vorinostat	DMWMPD4	Adult acute monocytic leukemia		Approved	[24]

5 Clinical Trial Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LCQ908	DMFLJHQ	Familial chylomicronemia syndrome	5C80	Phase 3	[25]
MURAGLITAZAR	DMG3NFZ	N. A.	N. A.	Phase 3	[26]
Rivoglitazone	DMBY31K	Ocular inflammation	9C61.24	Phase 3	[27]
TAK-875	DMIM5AP	Type-2 diabetes	5A11	Phase 3	[28]
Bevirimat	DML2D8Q	Human immunodeficiency virus infection	1C62	Phase 2	[29]

2 Discontinued Drug(s) Metabolized by This DME

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Gavestinel	DM8IL1U	Nerve injury	ND56.4	Discontinued in Phase 2	[5]
Licofelone	DM7HLFD	Osteoarthritis	FA00-FA05	Discontinued in Phase 1	[30]

References

• [1] Clinical pharmacokinetics and drug-drug interactions of endothelin receptor antagonists in pulmonary arterial hypertension. J Clin Pharmacol. 2012 Dec;52(12):1784-805.
• [2] In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole. Br J Clin Pharmacol. 2010 Dec;70(6):854-69.
• [3] UGT1A1*28 is associated with decreased systemic exposure of atorvastatin lactone. Mol Diagn Ther. 2013 Aug;17(4):233-7.
• [4] FDA Label of Baloxavir marboxil. The 2020 official website of the U.S. Food and Drug Administration.
• [5] Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
• [6] Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet Genomics. 2011 May;21(5):280-8.
• [7] Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos. 1998 Jun;26(6):507-12.
• [8] Drug-drug interaction potential of darolutamide: in vitro and clinical studies. Eur J Drug Metab Pharmacokinet. 2019 Dec;44(6):747-759.
• [9] Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554.
• [10] Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab Dispos. 2005 Jul;33(7):1027-35.
• [11] Empagliflozin (Jardiance): a novel SGLT2 inhibitor for the treatment of type-2 diabetes. P T. 2015 Jun;40(6):364-8.
• [12] Drug interactions between the immunosuppressant tacrolimus and the cholesterol absorption inhibitor ezetimibe in healthy volunteers. Clin Pharmacol Ther. 2011 Apr;89(4):524-8.
• [13] Comprehensive pharmacogenomic study reveals an important role of UGT1A3 in montelukast pharmacokinetics. Clin Pharmacol Ther. 2018 Jul;104(1):158-168.
• [14] Opioid therapies and cytochrome p450 interactions. J Pain Symptom Manage. 2012 Dec;44(6 Suppl):S4-14.
• [15] Variation in glucuronidation of lamotrigine in human liver microsomes. Xenobiotica. 2009 May;39(5):355-63.
• [16] FDA label of Lorlatinib. The 2020 official website of the U.S. Food and Drug Administration.
• [17] Pharmacogenomics of statins: understanding susceptibility to adverse effects. Pharmgenomics Pers Med. 2016 Oct 3;9:97-106.
• [18] S-Naproxen and desmethylnaproxen glucuronidation by human liver microsomes and recombinant human UDP-glucuronosyltransferases (UGT): role of UGT2B7 in the elimination of naproxen. Br J Clin Pharmacol. 2005 Oct;60(4):423-33.
• [19] Pitavastatin: a review in hypercholesterolemia. Am J Cardiovasc Drugs. 2017 Apr;17(2):157-168.
• [20] Retigabine N-glucuronidation and its potential role in enterohepatic circulation. Drug Metab Dispos. 1999 May;27(5):605-12.
• [21] Characterization of in vitro glucuronidation clearance of a range of drugs in human kidney microsomes: comparison with liver and intestinal glucuronidation and impact of albumin. Drug Metab Dispos. 2012 Apr;40(4):825-35.
• [22] Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10. Drug Metab Dispos. 2002 Dec;30(12):1462-9.
• [23] Effect of aging on glucuronidation of valproic acid in human liver microsomes and the role of UDP-glucuronosyltransferase UGT1A4, UGT1A8, and UGT1A10. Drug Metab Dispos. 2009 Jan;37(1):229-36.
• [24] Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr;6(4):563-85.
• [25] Pradigastat disposition in humans: in vivo and in vitro investigations. Xenobiotica. 2017 Dec;47(12):1077-1089.
• [26] Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism. Drug Metab Dispos. 2007 Dec;35(12):2270-80.
• [27] In vitro metabolism of rivoglitazone, a novel peroxisome proliferator-activated receptor gama agonist, in rat, monkey, and human liver microsomes and freshly isolated hepatocytes. Drug Metab Dispos. 2011 Jul;39(7):1311-9.
• [28] Disposition and metabolism of the G protein-coupled receptor 40 agonist TAK-875 (fasiglifam) in rats, dogs, and humans. Xenobiotica. 2019 Apr;49(4):433-445.
• [29] Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection. Antivir Chem Chemother. 2008;19(3):107-13.
• [30] In vitro metabolism of 2-[6-(4-chlorophenyl)-2,2-dimethyl-7-phenyl-2,3-dihydro-1H-pyrrolizin-5-yl] acetic acid (licofelone, ML3000), an inhibitor of cyclooxygenase-1 and -2 and 5-lipoxygenase. Drug Metab Dispos. 2008 May;36(5):894-903.